You-Tl and Antibiotic Stewardship Chances (With Challenges)


Ken Zangwill, MD
Chief, Division of Pediatric Infectious Diseases
Director, Infection Prevention and Control
Harbor-UCLA Medical Center
David Geffen School of Medicine at UCLA

Stewardship Opportunities



- Minimize overdiagnosis
- Process urine correctly
 - ◆ In fridge and/or <2 hrs to lab or use preservative</p>
- Judicious treatment & duration
- Limit antimicrobial prophylaxis
- D/C catheters ASAP

One Published QI Study on UTI in the NICU



UTI Risk Factors/Associations

- Gestational age
- GU abnormality
- Indwelling catheters actionable
- Length of stay
- ? Maternal UTI

Circumcision - protective

Etiology

- → E. coli (13-28%, higher in term babies)
- → K. pneumoniae (11-44%)
- Other GNR (21-27%)
- Enterococci (8-17%)
- → GBS (2-4%)
- ◆ S. aureus (1-3%)
- CoNS (13-23%, freq misclassification)
- Candida (6-15%, esp ELBWs)

Common Contaminants

- Lactobacillus sp.
- Corynebacterium sp.
- Coagulase-negative staphylococci
- Alpha-hemolytic streptococci (viridans)

UTI & Concomitant Bacteremia/Meningitis?

- 9-13% w/ bacteremia
 - GPC or candida predictive, but not BW
- 1-3% w/ meningitis

>1000 UTIs from Pediatrix NICUs

Proportion of UTIs concordant with blood and CSF cultures


Organism	Blood	CSF
Gram-positive cocci	52/318(16%)	2/24 (8%)
CoNS	30/146 (21%)	1/9 (11%)
Enterococcus	10/128 (8%)	0/10(0%)
Group B Streptococcus	6/24 (25%)	1/2 (50%)
Staphylococcus aureus	5/12 (42%)	0/2 (0%)
Gram-negative rods	34/478 (7%)	0/34 (0%)
Escherichia coli	10/173 (6%)	0/13 (0%)
Enterobacter	12/108 (11%)	0/8 (0%)
Klebsiella	4/92 (4%)	0/5 (0%)
Serratia	3/35 (9%)	0/2 (0%)
Pseudomonas	2/27 (7%)	0/4 (0%)
Proteus	2/13 (15%)	0/0
Candida	41/147 (28%)	0/19 (0%)


Neonatal UTI Long-term Followup

- 82 <34 GA Israeli babies</p>
 - No recurrences (but 28% w/o F/U)
 - 18/59 with in-person eval 11-22 yrs later:
 - No/NL renal U/S abnormalities, eGFR, prot/alb excretion, prot-Cr ratio, serum Cr
 - 4 with HTN (3 overweight)
- 18 Swedish babies: reduction in parenchymal thickness resolved by 17 yo

A Step Back...

Is the Diagnosis Correct?





Urinalysis Interpretation in the NICU

- Leukocyte esterase
 - False (+): gastroenteritis, urinary stones
 - False (-): neutropenia
- Nitrite
 - False (-): <4 hrs old, GPC bug</p>

A Bit About Pyuria

- Definition
 - Centrifuged (≥5/hpf)
 - Uncentrifuged w/ hemocytometer (≥10/mm³)
- False (-) is reasonably common
 - Adenovirus, enterovirus, HIV
 - Indwelling catheter
 - Renal stones
 - RTA & interstitial nephritis
 - NSAIDs
 - Congenital TB

Urinalysis Interpretation

Negative urinalysis (alone) does not R/O UTI in a neonate

Urine Collection for Culture

- SPA v catheterization:
 - More urine
 - Less contamination
 - Possibly more painful

Dump the first bit from cath specimen

Culture Interpretation

Source	Colony Count (cfu/ml)	UTI?	Comments
Cath or SPA	>50K	Yes	If symptomatic, cultures that grow 2 urine pathogens at >50K are consistent with a UTI.
Cath or SPA	10-50K	Suspected, esp w/ pyuria	
Cath	1-10K	Negative	
SPA	1-10K	Possible	Consider clinical context

This is no consensus on the diagnostic criteria for neonatal UTI so we have to be extra careful

UTI Treatment

System	Condition	Common Pathogens	Empiric Antibiotic Therapy	Antibiotic Duration
Neonatal Fever (Term Neonates)	Suspected UTI	E coli Enterococcus species GBS	Ampicillin PLUS Gentamicin	These are empiric recommendations; specific choice and duration of antibiotic therapy should be guided by culture results

UTI Treatment

- "Prelim GNR", call the lab for best guess
 - "fat" v "long thin"?
 - Avoid anti-pseudomonals
- Deescalate "R/O sepsis" regimen ASAP
- →≥7d duration, change to PO if NL LP
- No "test of cure" unless clinical failure

IV UTI Tx Duration & Recurrence <2m Olds

	100					
		3 d		3 d		
Study	Events	Total	Events	Total	UTI Recurrence	OR [95% CI]
Díaz Álvarez, 2006	5	95	3	99		1.78 (0.41 to 7.65)
Magín, 2007	0	56	0	116		2.06 (0.04 to 105.26)
Schroeder, 2016	0	30	7	168	-	0.35 (0.02 to 6.34)
Lewis-de los Angeles, 2017	42	2739	19	1234	-	1.08 (0.60 to 1.93)
Desai, 2019	1	17	5	98		1.16 (0.13 to 10.61)
Fernandez, 2020	4	279	1	43		0.61 (0.07 to 5.60)
Lessard, 2020	5	54	6	54	_	0.87 (0.19 to 3.94)
Goeller, 2020	0	18	2	46		0.48 (0.02 to 10.51)
Swartz, 2020	1	106	4	87	-	0.40 (0.02 to 6.70)
Marsh, 2020	1	86	0	26		0.93 (0.04 to 23.51)
Overall (Random-Effects Model) Heterogeneity: $I^2 = 0\%$, $\tau^2 = 0$, $\chi_q^2 = 2.14$	59	3480	47	1971	+	1.02 (0.64 to 1.61)
116.610galletty. 1 = 0/6, τ = 0, χ _g = 2.14	(P = .55)				0.01 0.1 1 10 10	00
					Favors ≤3 d Favors >3	3 d

No diff with 0-1m v 1-2m or +/- bacteremia No prospective data, no stratification by GA

Should Concomitant Bacteremia Change IV Duration?

- Probably not...
 - Clinical and lab findings generally similar
 - No association between IV duration and relapse in children <2m
 - Fewer data for preemies

Antimicrobial Prophylaxis?

Scenario	Prophylactic Antibiotics?
Urinary tract dilation <i>in utero</i>	Possibly, if high grade
1 st UTI	No
2 nd UTI	Discuss with ID
Indwelling catheter in place	No


Prophylaxis & in utero Urinary Tract Dilation?

- Most resolve spontaneously
- ~50% of clinicians don't even if high level
- In first month, incidence = to gen pop (~0.1%)
- Get U/S within 2-4 weeks (Soc Fetal Urol)


TABLE 3. Common Medications Used for CAP

MEDICATION	TREATMENT DOSE	CAP DOSE	FDA-APPROVED INDICATIONS	COMMON ADVERSE EFFECTS
Amoxicillin	25–45 mg/kg per day PO divided into 2 doses	15–20 mg/kg daily	Any age, UTI treatment	Cutaneous/allergic reactions, gastrointestinal disturbances
Cephalexin	25–50 mg/kg per day PO divided into 2–4 doses	25 mg/kg daily or divided into 1–2 doses	Any age, UTI treatment	Cutaneous/allergic reactions, gastrointestinal disturbances
Nitrofurantoin	5–7 mg/kg daily divided into 4 doses	1–2 mg/kg daily	>1 month age, UTI treatment or prophylaxis	Hemolytic anemia, gastrointestinal disturbances, interstitial pneumonitis, cutaneous/allergic reactions
TMP	8–10 mg/kg TMP daily divided into 2 doses	2 mg/kg TMP daily	>12 years age, UTI treatment or prophylaxis	Cutaneous/allergic reactions, hematologic toxicity
TMP- sulfamethoxazole	8–10 mg/kg TMP daily divided into 2 doses	2 mg/kg TMP daily	>2 months age, UTI treatment or prophylaxis	Cutaneous/allergic reactions, hematologic toxicity, hepatotoxicity (kernicterus)


U Wisconsin NICU ASP QI/PDSA



U Wisconsin NICU ASP QI/PDSA



U Wisconsin NICU ASP QI/PDSA



No increase in subsequent SBI, more resp support, NEC, death

Stewardship Opportunities

TOPPORTUNITY

- Minimize overdiagnosis of UTI
 - Seriously consider other diagnoses
- Process urine correctly
- Judicious UTI treatment/duration
 - Consider a guideline (thanks UCI)
 - → 7d fine, not >10d
 - PO OK if tolerable
- Limit antimicrobial prophylaxis:
 - → In utero urinary tract dilation? Possibly
 - After any neonatal UTI? No
 - After recurrent UTI? Possibly
- Indwelling catheter
 - Pyuria not sufficient to Dx CAUTI

Thank you

AAP Red Book Committee is developing an ASP guideline for the NICU!

Should I Do Imaging?

	Renal/bladder Ultrasound
1 st UTI	All patients
2 nd UTI	All patients

Ultrasound a poor predictor of VUR 30-50% may have abnormalities, <10% severe

Should I Do Imaging?

	Renal/bladder Ultrasound	VCUG
1 st UTI	All patients	If RBUS is abnormal or if severe illness (eg, prolonged instability, AKI, gross hematuria, etc.)
2 nd UTI	All patients	All patients

Ultrasound a poor predictor of VUR 30-50% may have abnormalities, <10% severe

VCUG Results in Those With UTI

Birthweight	Abnl VCU (%)
<1000g	8-16
1000-1500g	10-23
>1500g	18
<1500g	7-16
All birthweights	4-14

If VUR, **nearly all**Grade I-II; <5% with ≥ Gr III

UTI Prevalence

Gestational Age/Birthweight	Percent with UTI
≤28 wks	8-13
28-33 wks	3-23
>33 wks	1.1
Term	0.1-1

<1% in first few days...